Life writes the questions We pursue the answers
|
|
- Jack Porter
- 7 years ago
- Views:
Transcription
1 Life writes the questions We pursue the answers
2 Life writes the questions. 1
3 What will help me?
4 Can I have hope?
5 When will the others notice?
6 How much life is six months?
7 How bad can it get?
8 Am I alone?
9 What about my family?
10 Will my life change?
11 What if I m not ready yet?
12 What s fair?
13 How can I protect us?
14 How many summers have I got left?
15 Have I expected too much?
16 Should I fight?
17 How much longer?
18 Aren t I too young?
19 Who can tell me if I m doing the right thing?
20 Is it right to give up?
21 Is there a solution?
22 When it comes to disease there are as many questions as people. We can t provide an answer to them all but we can help with our expertise
23 Innovation is our answer to medical challenges. Our daily work issaving patients lives and helping millions of people around the world. We continuously invest in medical research and development to provide new drugs and diagnostic products for conditions such as cancer,aids, hepatitis, Alzheimer s disease, rheumatoid arthritis and diabetes
24 Roche in a nutshell We discover, develop and deliver innovative diagnostic and therapeutic products and services that transform patients lives and bring real benefits from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. Focus on unsolved medical problems Broad access to innovation Personalised medicine an interplay of diagnosis and treatment For more than 110 years Roche has played a pioneering role in healthcare. Today, as world leader in in-vitro diagnostics, we supply a wide range of diagnostic instruments and tests for rapid and reliable disease detection and monitoring by doctors, laboratories or patients themselves. In the therapeutic fi eld, Roche has brought many highly effective drugs onto the market in the last few years. Our daily work focuses on disease areas where medical needs are great. These include cancers, viral infections, metabolic and central nervous system disorders and inflammatory diseases. Roche is the world s leading supplier of prescription drugs for cancer treatment. Roche invests heavily in the research and development of new drugs and diagnostic products and complements its own worldwide research activities with a wealth of cooperation agreements with universities, research institutes and biotech companies. This network and our majority stakes in Genentech in the USA and Chugai in Japan provide us with broad access to innovation. As the world s largest biotech company, we exploit the latest discoveries and technologies to develop our products. Together with our partners we turn the multiplicity of ideas into medical solutions. The rapid progress in research gives us important insights into the molecular mechanisms of disease. We also know that two people can react differently to the same medication and that this is based on variations in our genes. Personalised medicine takes these new discoveries into account in the development of drugs and diagnostic tests. Roche plays a pioneering role in this area and is already marketing the first personalised medicinal products that are tailored to the needs of specific patient groups
25 Oncology 1,000,000,000 7,000, US $ investment hours of work experiments researchers drug Cancer is not a single, static disease. It is a complex condition of which over 250 types have been identified so far. Its development involves a multitude of changes in the affected cells, and this makes it difficult to fi ght. World leader in innovative cancer drugs Roche currently has a number of innovative cancer drugs on the market. They give patients the most important thing in life: time to live. Five of these drugs Herceptin, Avastin, MabThera/Rituxan, Xeloda and Tarceva offer clear survival benefits in different types of cancer and each has its own unique mechanism of action that halts tumour growth. In addition to these products, we supply a variety of therapies that help to ease the possible side effects associated with cancer treatment. Precise diagnosis the key to successful treatment Precise diagnosis is the key to successful treatment. Biomarkers, i.e. components of our body cells that can be used as indicators for the disease, will enable doctors to determine which cancer type a patient has much more quickly and specifically. We are also working to identify tumour markers that will detect tumour cells long before the first symptoms become apparent. This information will help physicians to initiate targeted and effective treatment without delay, thereby enhancing patient well-being and decreasing the cost to the healthcare system. Roche searches for potential cures Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved. This helps our scientists to target the processes that lead to cancer. This is an area where biopharmaceuticals, and especially highly specific antibodies, play an important role. Our goal is to use modern technologies to make these biopharmaceuticals even more effective in the future. Cancer remains the second leading cause of death in the industrialised world and its incidence is growing. But if detected early enough, many forms of the disease can be effectively treated. Figures are approximate
26 Virology The revolution in our diagnostic instruments Viral diseases are an insidious and serious health hazard. Viruses are often not detected early enough, which allows them to spread uncontrolled. Their infinite adaptability also makes them hard to target and trap. Flu, hepatitis and HIV/AIDS are some of the most widespread viral infections. Once upon a time, only temperatures were taken to give an indication of illness. Today s molecular medicine offers new diagnostic techniques and treatments to relieve suffering, limit new infections and reduce mortality. Flu is a real challenge to our immune system Every year flu viruses attack the immune systems of 100 million people in Europe, Japan and the USA alone, and up to 500,000 people die each year worldwide. By changing their profile slightly every year, they make it difficult for our immune system to fi ght them off. In a joint project, Roche and Gilead developed Tamiflu, a drug that attacks the flu virus and is now used throughout the world for the treatment and prevention of influenza. Early detection of hepatitis increases the likelihood of cure Hepatitis is a viral infection that can go undetected in the body for years. Left untreated, it can lead to cirrhosis, liver failure and cancer. Detection and treatment are essential in the early stages when the likelihood of cure is relatively high. Tests that diagnose and monitor the virus in the blood and treatment with our biotech drug Pegasys have helped many of the people who have been infected. Unfortunately, not all patients respond equally well to this treatment. That s why we re working intensively on new strategies to provide effective treatment to more patients. New mechanisms of action help those living with HIV/AIDS HIV/AIDS remains incurable. But deaths from AIDS have declined dramatically in recent years. This is due in no small part to modern molecular diagnostics whose capacity for rapid, reliable and routine detection and monitoring of the virus and virus resistance enables patients treatment to be adjusted accordingly. We are proud to have developed two entirely new classes of effective drugs that represent major breakthroughs for HIV treatment and patients. Roche responds to global challenges The world s poorest countries have access to our virology products. By adopting a combination of tiered pricing, a flexible patent policy and technology transfer initiatives, we re making it easier for them to address their healthcare challenges. We re working in partnership with the World Health Organization (WHO), committed governments, non-governmental organisations and other stakeholders to develop solutions that benefit the least developed countries
27 Metabolism This drop can save lives Regulation of our body s blood sugar level is a vital yet delicate balance, which can easily be disrupted. The result is diabetes. The WHO estimates that more than 180 million people worldwide suffer from diabetes. Type 2 diabetes the commonest form of the disease is now recognised globally as a growing epidemic. Independence for people with diabetes Diabetes isn t a disease you can necessarily feel to detect it and keep it under control, there s no substitute for regularly checking your blood sugar levels. Testing takes just a single drop of blood and a few minutes. We offer a wide range of products that make it easy for people with diabetes to check their blood sugar levels consistently in day-to-day situations. Roche the leader in diabetes care For over 30 years our Accu-Chek blood glucose meters have ensured precise and rapid blood sugar measurement both at home and on the move. Not only that, they have become increasingly easy to operate. State-of-the-art measurement, infusion and data processing systems help doctors and patients to implement comprehensive diabetes management and hence optimise treatment. Regular blood sugar monitoring gives people with diabetes a major advantage, enabling them to lower the risk of potentially life-threatening complications. Diabetes prevention in Africa The number of people with type 2 diabetes appears to be increasing significantly in rural South Africa. The Phelophepa train, a South African community health clinic on rails which Roche has sponsored since its inception, helps people to prevent the onset of diabetes and to recognise its symptoms. The train brings primary healthcare services, general medical care and health education programmes to rural areas. Roche s commitment to Phelophepa exemplifies our philosophy of collaborative and sustainable corporate donations. We believe in supporting novel, practical solutions that are tailored to local conditions and needs and that can be implemented in conjunction with committed local partners. Diabetes is a complex chronic disease. But it can be controlled through a combination of the right lifestyle, good health management and new treatment strategies. The core component in controlling diabetes is careful blood sugar monitoring. New research strategies focus on metabolism Researching new drugs against diabetes means taking a patient s metabolism into account. Recognising that obesity, lipid metabolism disorders and high blood pressure are closely associated with diabetes, Roche is testing various compounds that act at key metabolic interfaces. At the same time we re using a new comprehensive approach called systems biology to research the central role played by the body s insulin-producing cells
28 Inflammation Our contribution to enhancing quality of life Rheumatoid arthritis is one of the most common autoimmune diseases, affecting more than 21 million people worldwide. In 30 40% of cases conventional drugs are ineffective or poorly tolerated. Now, biopharmaceuticals are paving the way for a new treatment that can impede progression of the disease and prevent joint damage and pain. Roche goes to the root of the disease Our researchers are looking to deepen their understanding of the immune system and pinpoint the causes and course of arthritis. Their discoveries have already resulted in new drugs offering real patient benefits. Biopharmaceuticals such as MabThera/ Rituxan in rheumatoid arthritis selectively intervene in the molecular course of the disease without weakening the immune system as a whole. This new mechanism of action alleviates pain and holds the disease in check. The earlier the diagnosis, the better Currently doctors rely on a constellation of signs and symptoms to make a firm diagnosis of rheumatoid arthritis. By that time many patients are already disabled by their damaged joints. Our goal is earlier detection using a reliable disease indicator in the form of a biomarker incorporated in a diagnostic test. Only then will doctors be able to intervene early enough to prevent joint damage and disability. Intensive collaboration with patient organisations It is important to us to gain a greater understanding of what it is like to live with this and other diseases, and to comprehend the challenges facing patients and their families. That s why we collaborate closely with different patient organisations to gain knowledge, for example, about disease-related problems or the user-friendliness of drugs which only they can supply. This cooperation also enables Roche to gather experience that is channelled into support for doctors and nursing staff, and in this way benefi ts patients. We speak of an autoimmune disease when the body turns on itself and the immune system mistakes self for non-self. Innovative biopharmaceuticals offer a defence against this autoimmune attack
29 Central nervous system The most effective drug when it comes to the brain Central nervous system disorders are among the world s greatest unresolved health problems, and Alzheimer s disease is one of the biggest threats facing aging industrial societies. There is currently no prospect of a cure for Alzheimer s, only the possibility of slowing its progression. Fighting forgetfulness with therapeutic antibodies We re thinking outside the box to attack the disease at its root. We re researching various strategies for dissolving the brain deposits, known as plaques, that are characteristic of Alzheimer s disease. One promising approach, identified in collaboration with a partner, is based on a human therapeutic antibody that is custom-designed for this purpose. Patients will benefit because removal of the deposits has been linked to improved cognitive functioning. New perspectives for schizophrenia patients Years of research on the central nervous system is leading us in new directions and towards innovative approaches to the treatment of schizophrenia. We have discovered compounds that differ in their mechanism of action from the classical antipsychotics currently used to treat schizophrenia. This may bring fresh hope to patients with psychiatric disorders. Responsible action Research entails responsibility. That s why we ve always applied the highest ethical standards in research and development, reflected for example in our guidelines governing genetic research or clinical trials. Before a drug comes to market a regulatory authority must approve it. This approval process includes pre-clinical laboratory and animal studies, as well as clinical trials to demonstrate the safety and efficacy of the drug. We believe that we have an ethical obligation to inform the public about our clinical trials and their results so that this information can be helpful to patients and physicians. Developing effective drugs for diseases such as Alzheimer s, schizophrenia or depression is a major challenge. Nevertheless, research in these areas has progressed enormously in the last few decades
30 Personalised medicine This molecule makes the difference Our aim is to continue tailoring medicine as closely as possible to patients needs. As one of the world s leading healthcare companies, and given our combined strengths in pharmaceuticals and diagnostics, there s no one better suited for the task of developing personalised medicine. People are different and so are diseases Individuals react differently to specific medications due to the variations in their genes. Moreover, many diseases occur in genetically distinct subtypes that vary in their clinical course and prognosis. Thus, two patients who seemingly have the same disease and are treated with the same medicine may respond in radically different ways. One may benefit fully from treatment, while the other experiences unwanted side effects or derives no clinical benefit at all. Variations in our genes How well certain drugs work depends in many cases on specific gene variations in patients. A modern DNA chip (AmpliChip CYP450 test) enables doctors to identify these variations in a minute amount of DNA. Based on this knowledge, they can then adjust treatment accordingly. As a result patients receive the right dosage of the right drug, which leads to a better treatment outcome. Medicine is becoming increasingly personalised Over the last few years Roche has given various examples in the fields of cancer treatment and viral diseases of how the interweaving of diagnostic and pharmaceutical expertise paves the way for personalised medicine. Our aim is to provide healthcare professionals with more powerful diagnostic tools and targeted treatments based on the new insights into how diseases arise at the molecular level. Setting our sights on the future We re convinced that only innovation can maintain the requisite quality of healthcare over the long term. Innovation is the core of our strategy and the key to safer, more cost-effective and more people-friendly medicines. Every patient expects the best possible treatment. Science helps to provide it. Growing insights into the causes and progression of diseases on a molecular level offer the opportunity to improve the way we diagnose and treat disease. People are different, and for that reason one size does not fi t all
31 There are as many answers as people. We continue to research individual solutions
32 Published by F. Hoffmann-La Roche Ltd Corporate Communications 4070 Basel, Switzerland 2008 All trademarks mentioned enjoy legal protection. This brochure is available in German, English, Spanish and French. Printed on FSC-certified paper Concept and design Interbrand Zintzmeyer & Lux, Zurich Printed in Switzerland by Birkhäuser + GBC, Reinach BL World Wide Web 60
33 Published by F. Hoffmann-La Roche Ltd Corporate Communications 4070 Basel, Switzerland 2008 All trademarks mentioned enjoy legal protection
If you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationInnovation in the Pharmaceutical Industry Future Prospects
r Innovation in the Pharmaceutical Industry Future Prospects Talk by Dr Franz B. Humer, Chairman of the Board of Directors and CEO of F. Hoffmann-La Roche Ltd, to the Zürcher Volkswirtschaftliche Gesellschaft
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationPersonalised Healthcare Frequently Asked Questions
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationAnnual General Meeting of Roche Holding Ltd 2 March 2010
r Annual General Meeting of Roche Holding Ltd 2 March 2010 Address by Severin Schwan CEO of the Roche Group (Check against delivery.) Address by Severin Schwan Page 2 of 14 Ladies and Gentlemen, Fellow
More informationRoche in Switzerland Innovation is our home
Roche in Switzerland Innovation is our home Roche s sites in Switzerland in context Roche was founded by Fritz Hoffmann-La Roche on 1 October 1896. He was one of the first people to recognise that major
More informationRoche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationRoche Position on Access to Medicines and Diagnostics
Roche Position on Access to Medicines and Diagnostics MISSION Our primary role in improving access to medicines and diagnostics is through the research, development & commercialisation of innovative medicines
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationChapter 21. What Are HIV and AIDS?
Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome
More informationOur values help us to create added value in a sustainable way. Sustainability includes fostering and retaining our most talented employees
Our values help us to create added value in a sustainable way Sustainability includes fostering and retaining our most talented employees 32 Sustainability Report 2004 Creating value through sustainable
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationHemophilia Care. Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future?
Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the
More informationnovo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices
novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Juan Jenny Li works as a chemistry professional at Novo Nordisk s research centre in Beijing Diabetes Protein Technologies
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationTHE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme
THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to
More informationCancer Treatment Moringa Oleifera for Cancer Prevention or Treatment
Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment As we learn more about cancer, we are empowered to use more of the tools which nature has created for us to help battle this terrible
More informationInformation for patients and the public and patient information about DNA / Biobanking across Europe
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
More informationDiabetes & blindness. due to DME BLINDNESS IN EUROPE
Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationMutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base
Mutations Mutations: 2 general ways to alter DNA Change a single DNA base Or entire sections of DNA can move from one place to another What is a mutation? Any change in the nucleotide sequence of DNA Here
More informationA guide for the patient
Understanding series LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS The Basics What is a Clinical Trial?...3 Types of Clinical Trials... 3 Phases
More informationOne of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types:
Immune system. One of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types: (pathogen - disease causing organism) 1) Non specific. Anything foreign
More information1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease
The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationBiologics Biosimilars
Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But
More informationBile Duct Diseases and Problems
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
More information91,747 employees in over 100 countries
Roche in Brief 2015 Roche Who we are Who we are Roche Who we are 91,747 employees in over 100 countries CHF 48.1 bn in Group sales in 2015 # 1 in biotech, oncology, in vitro diagnostics and hospital market
More informationWhy Disruptive Innovations Matter in Laboratory Diagnostics
Article: S. Nam.. Clin Chem 2015;61:935-937. http://www.clinchem.org/content/61/7/935.extract Guest: Spencer Nam is a Research Fellow specializing in healthcare at the Clayton Christensen Institute for
More informationSusan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer. Judith A. Salerno, M.D., M.S. President and Chief Executive Officer
Susan G. Komen: A Promise Renewed Advancing the Fight Against Breast Cancer Judith A. Salerno, M.D., M.S. President and Chief Executive Officer Summer 2014 Who We Are: Executive Summary In just 32 years,
More informationTechnological Advances in the Medical Field, Human Health and Aging
1 EGN 1033 Technology Humans and Society Technological Advances in the Medical Field, Human Health and Aging Tatiana Fuentes Daniel Garcia Beatriz Varela Florida International University 10555 West Flagler
More informationThe National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationTreating Depression to Remission in the Primary Care Setting. James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health
Treating Depression to Remission in the Primary Care Setting James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health 2007 United Behavioral Health 1 2007 United Behavioral Health Goals
More informationSUPPORT KNOWLEDGE QUALIFY PETROCTM
SUPPORT KNOWLEDGE QUALIFY PETROCTM DISTANCE LEARNING Courses for the caring professions, and more Distance learning courses for caring careers Certificate in Mental Health Awareness...... 3 Certificate
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationehealth 2.0: How health systems can gain a leadership role in digital health Gerardo Aue, Stefan Biesdorf, Nicolaus Henke
ehealth 2.0: How health systems can gain a leadership role in digital health Gerardo Aue, Stefan Biesdorf, Nicolaus Henke Health systems around the world clearly recognise the potential of digital health;
More informationClinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved
Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationThe Immune System and Disease
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
More informationThe link between cervical cancer and HPV (human papillomavirus)
The link between cervical cancer and HPV (human papillomavirus) The link between cervical cancer and HPV Key facts: HPV is a virus (the human papillomavirus). Almost all abnormal Pap smear results are
More informationAntipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Patient Tool #1 Understanding Diabetes and Psychiatric Illness: A Guide for Individuals, Families, and Caregivers Type 2 Diabetes,
More informationPAIN MANAGEMENT AT UM/SYLVESTER
PAIN MANAGEMENT AT UM/SYLVESTER W HAT IS THE PURPOSE OF THIS BROCHURE? We created this brochure for patients receiving care from the University of Miami Sylvester Comprehensive Cancer Center and their
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationCLINICAL CLINICAL TRIALS. How Clinical Trials Work for Children
CLINICAL CLINICAL TRIALS How Clinical Trials Work for Children Today, there are only a handful of drugs approved by the U.S. Food and Drug Administration (FDA) to treat hepatitis B, C or D in adults. There
More informationWhat do you know about HbA1C
Did you know? Essential advice for people with diabetes from Accu-Chek HbA1C is a measure of your average blood glucose level over 3 months Your HbA1C target should be under 53mmol/mol It is important
More informationPoint of care analyzer for definitive cystic fibrosis diagnostics
Technology Offer Summary Point of care analyzer for definitive cystic fibrosis diagnostics A Barcelona based company offers a CE (Conformité Européenne) marked diagnostic test system for the measurement
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationBorderless Diseases By Sunny Thai
Borderless Diseases By Sunny Thai Millennium Development Goal #6 6. Combat HIV/AIDS, malaria and other borderless diseases. A. Halt and begin reversing spread of HIV by 2015. B. Achieve universal access
More informationChapter 3 Type 1 Diabetes
Chapter 3 Type 1 Diabetes Type 1 diabetes is one of the most common chronic disorders of childhood. Unfortunately, it is increasing in incidence, particularly in young children. The reason for this is
More informationPatient Rights (Scotland) Bill. Roche Products Ltd
Patient Rights (Scotland) Bill Roche Products Ltd Roche is a leading manufacturer of innovative medicines, including in oncology, rheumatology and virology. We have expertise in a wide range of medical
More informationWHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationVision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision
Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Medicine Initiative: Building a Large U.S. Research Cohort
More informationRoutine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationStem cell research ACADEMY STATEMENT. progress, hopes and concerns ACADEMY STATEMENT 16 JANUARY 2013
ACADEMY STATEMENT 16 JANUARY 2013 ACADEMY STATEMENT Stem cell research progress, hopes and concerns KUNGL. VETENSKAPSAKADEMIEN, BOX 50005, SE-104 05 STOCKHOLM, SWEDEN TEL +46 8 673 95 00, FAX +46 8 15
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationViral hepatitis. Report by the Secretariat
SIXTY-THIRD WORLD HEALTH ASSEMBLY A63/15 Provisional agenda item 11.12 25 March 2010 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses (hepatitis A, B, C, D and
More informationUnderstanding Clinical Trials
Understanding Clinical Trials The UK Clinical Research Collaboration (UKCRC) is a partnership of organisations working to establish the UK as a world leader in clinical research, by harnessing the power
More informationFAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.
HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV
More informationPersonalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationThe Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
More informationLiver Function Essay
Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working
More informationTop Ten Things to Know About Stem Cell Treatments
Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationName Date Class. This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread.
Fighting Disease Name Date Class Infectious Disease This section explains what kinds of organisms cause infectious disease and how infectious diseases are spread. Use Target Reading Skills Before you read,
More informationRoche reports solid sales growth in the first quarter of 2016
Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increase
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationMonoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C
Monoclonal Antibody Therapy: Innovations in Cancer Treatment James Choi ENGL 202C Treating Cancer with Monoclonal Antibody Therapy Researchers and scientists have been working for decades to find a cure
More informationPPS UNDERWRITING GUIDE FOR APPLICANTS
PPS UNDERWRITING GUIDE FOR APPLICANTS UNDERWRITING guide 2013 WHAT HAPPENS WHEN YOU SUBMIT YOUR APPLICATION FOR INSURANCE? Once an application is submitted it is put through a number of processes to ensure
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More informationEYE DISEASES IN HIV-INFECTED INDIVIDUALS IN RURAL SOUTH AFRICA
EYE DISEASES IN HIV-INFECTED INDIVIDUALS IN RURAL SOUTH AFRICA In our Western world where treatment is available, HIV/AIDS has become a chronic disease. In all other parts of the globe, HIV/AIDS is still
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationThe Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION
The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION What Is Alpha-1 Antitrypsin Deficiency? Alpha-1 is a condition that may result in serious lung disease in adults and/or liver
More informationCRITICAL ILLNESS INSURANCE. ExtensiA. The ideal complement to your group insurance
CRITICAL ILLNESS INSURANCE ExtensiA The ideal complement to your group insurance Peace of mind within your reach Today, progress in medicine and breakthroughs in research have significantly extended our
More informationBASIC INFORMATION ABOUT HIV, HEPATITIS B and C, and TUBERCULOSIS Adapted from the CDC
BASIC INFORMATION ABOUT HIV, HEPATITIS B and C, and TUBERCULOSIS Adapted from the CDC HIV What are HIV and AIDS? HIV stands for Human Immunodeficiency Virus. This is the virus that causes AIDS. HIV is
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationSaving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases
Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Jeff Gulcher, MD PhD Chief Scientific Officer and co-founder decode
More informationNine-month sales show continued double-digit growth significantly above the market average
Investor Update Basel, 14 October 2004 Nine-month sales show continued double-digit growth significantly above the market average Roche Group Sales in core businesses up by 14%* to 21.9 billion Swiss francs
More informationIl ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020
Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:
More information1.How did I get Hepatitis C?
1.How did I get Hepatitis C? Sharing needles and syringes ( iv drug use ) or using contaminated straws to snort cocaine Reused needles or medications in a health care setting- (LV endoscopy outbreak, glucometers
More informationHUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE
HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous
More informationDIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa
DIABETES A chronic, debilitating and often deadly disease Diabetes is a chronic condition that arises when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin
More informationUsing Family History to Improve Your Health Web Quest Abstract
Web Quest Abstract Students explore the Using Family History to Improve Your Health module on the Genetic Science Learning Center website to complete a web quest. Learning Objectives Chronic diseases such
More information